Go­ing gang­busters in atopic der­mati­tis, the FDA hands Sanofi and Re­gen­eron a fresh coup for their mega-block­buster star Dupix­ent

Just days af­ter Sanofi CEO Olivi­er Brandi­court proud­ly showed off the phar­ma gi­ant’s re­turn to growth with the stel­lar per­for­mance of Dupix­ent lead­ing the way, the French com­pa­ny and its long­time al­lies at Re­gen­eron laid claim to a fresh coup for the fran­chise, gain­ing a pri­or­i­ty re­view des­ig­na­tion at the FDA for ex­pand­ing the drug’s reach to ado­les­cents with mod­er­ate to se­vere atopic der­mati­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER